EZH2 inhibitors for treating lymphoma
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
1. A method for treating marginal zone lymphoma (MZL) in a subject comprising administering an EZH2 inhibitor to the subject.
2. The method of claim 1 , wherein the EZH2 inhibitor is administered orally.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 3 , wherein the EZH2 inhibitor is EPZ-6438 having the following formula:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
6. The method of claim 4 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID to about 1600 mg BID.
7. The method of claim 4 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or 1600 mg BID.
8. The method of claim 7 wherein the EZH2 inhibitor is administered to the subject at a dose of 800 mg BID.
9. The method of claim 3 , wherein the EZH2 inhibitor is:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the EZH2 inhibitor is:
or a pharmaceutically acceptable salt thereof.